Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70. Objectives: To see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe. Eligibility: Adults age 18 and older diagnosed with cancer that has the CD70-expressing cancer. Design: Participants will be screened with medical history, physical exam, scans, and other tests. They may by admitted to the hospital. Leukapheresis will be performed. For this, blood is removed through a needle in the arm. A machine separates the white blood cells. The rest of the blood is returned through a needle in the other arm. Eligible participants will have an intravenous catheter placed in their upper chest. Over several days, they will get chemotherapy drugs and the anti-CD70 cells. They will recover in the hospital. Participants will take an antibiotic for 6 months after treatment. They will repeat leukapheresis. Participants will visit the clinic every 1-3 months for the first year after treatment, every 6 months for the second year, and then as determined by their physician. Follow-up visits will take 1-2 days. At each visit, participants will have lab tests, imaging studies, and a physical exam. Throughout the study, blood will be taken and participants will have many tests to determine the size and extent of their tumor and the treatment s impact.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorośli w wieku 18 lat i starsi, zdiagnozowani z nowotworem, który produkuje białko CD70.
- •Choroba nowotworowa nieoperacyjna lub taka, która nie zareagowała na wcześniejsze leczenie.
- •Potwierdzenie diagnozy nowotworu przez specjalistyczne laboratorium.
- •Obecność zmian przerzutowych w mózgu ograniczona do 3 małych, bezobjawowych zmian lub zmian po leczeniu, które są stabilne od miesiąca.
- •Wiek pacjenta od 18 do 72 lat.
- •Ogólny stan zdrowia pozwalający na aktywność (grupa 0 lub 1 w skali ECOG).
- •Zgoda na stosowanie antykoncepcji przez kobiety (przez 12 miesięcy po leczeniu) i mężczyzn (przez 4 miesiące po leczeniu).
✗ Disqualifies
- •Ciąża lub niemożność stosowania antykoncepcji.
- •Niektóre choroby mogą wpływać na wyniki testów ciążowych.
- •Choroby, które mogłyby utrudnić ocenę skuteczności lub bezpieczeństwa leczenia.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 72 Years
- Last updated (source)
- June 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
NCI SB Immunotherapy Recruitment Center
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.